Press Releases

February 12, 2020 | Synspira Therapeutics and Cystic Fibrosis Foundation Sign Agreement to Develop Broad-spectrum Enzyme Replacement for Malabsorption Syndromes

October 31, 2019 | Synspira Therapeutics Presents Data on Effect of SNSP113 on Chronic, Recalcitrant Nontuberculosis Mycobacteria (NTM) Pulmonary Infections at 33rd Annual North American Cystic Fibrosis Society Conference

October 28, 2019 | Synspira Therapeutics Appoints Industry Leaders Dr. Alexey Margolin And Robert K. Coughlin To Board Of Directors

April 23, 2019 | Synspira Therapeutics SNSP 113 Demonstrates Improvement in Abnormal Cystic Fibrosis Mucus and Pulmonary Disease

April 10, 2019 | Synspira Therapeutics Receives Orphan Designation for SNSP113 for the Treatment of Cystic Fibrosis in the European Union

March 27, 2019 | Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer

October 12, 2018 | Synspira Announces Abstracts Evaluating New Treatment Options for Cystic Fibrosis Complications Accepted for Presentation at the 32nd Annual North American Cystic Fibrosis Conference

October 11, 2018 | Synspira Receives U.S. FDA Orphan Designation for SNSP113 for the Treatment of Cystic Fibrosis

August 09, 2018 | Synspira’s PAAG Therapy Demonstrates Persistence Against Pseudomonas aeruginosa Persister Cells

January 17, 2018 | Synspira’s Novel Glycopolymer Proves Effective Against Antibiotic Resistance

January 03, 2018 | Synspira Announces $3 Million Development Award from Cystic Fibrosis Foundation

November 02, 2017 | Synspira Announces Data for Lead Candidate at the 31st Annual North American Cystic Fibrosis Conference

October 18, 2017 | Synspira Announces First Patient Dosed in Phase 1a Study of SNSP113 in Cystic Fibrosis

July 12, 2017 | Synspira’s Novel Glycopolymer Improves Effectiveness of Antibiotics Against Drug-resistant Bacteria Associated with Cystic Fibrosis

June 29, 2017 | Synspira Announces $8 Million in Funding and Board of Directors